Ennov, a leading provider of unified compliance software solutions for the Life Sciences, is pleased to announce a strategic partnership with CognifAI, an innovative AI solutions company specializing in pharmacovigilance. This collaboration aims to integrate CognifAI’s advanced AI-driven literature monitoring solution, CoVigilAI, into Ennov’s comprehensive pharmacovigilance offering.

The partnership will provide Ennov’s customers with state-of-the-art AI technology to streamline literature monitoring activities and enhance compliance with regulatory requirements. By leveraging CoVigilAI’s capabilities, customers can expect improved efficiency.

“At CognifAI, we believe that collaboration fuels innovation. Our partnership with Ennov is a testament to that belief. Together, we’re unlocking new possibilities with our AI-driven literature monitoring solution for PV, CoVigilAI. This partnership will help CognifAI take CoVigilAI globally to Ennov’s customers. Together, our mission is to enhance patient safety and streamline adverse event reporting.”

– Hemang Naik, CEO of CognifAI

“We are thrilled to join forces with CognifAI to bring next-generation AI solutions to our customers. This partnership aligns perfectly with our commitment to innovation and excellence in pharmacovigilance. By integrating CoVigilAI into our platform, we are providing our customers with powerful tools to enhance patient safety and stay ahead of the competition.”

– Olivier Pâris, CEO of Ennov

About CognifAI

CognifAI is an innovative AI solutions company specializing in pharmacovigilance. Leveraging data from sources like Pubmed, Embase, and more, CognifAI provides cutting-edge AI-driven solutions to revolutionize literature monitoring and adverse event reporting, enhancing patient safety worldwide.

For more information, visit www.CognifAI.in or contact us at [email protected].